Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion

CHARLES EDO DE BOCK1,2*, ZHEN LIN1*, AHMED H. MEKKAWY1, JENNIFER A. BYRNE3 and YAO WANG1,4

1Division of Critical Care and Surgery, St. George Hospital, University of New South Wales, Kogarah, Sydney, NSW 2217;  
2Leukaemia Foundation Research Laboratory, The Queensland Institute of Medical Research, Brisbane, QLD 4029;  
3Children’s Cancer Research Unit, The Children's Hospital at Westmead, NSW 2145, Australia;  
4The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, P.R. China

Received December 15, 2009; Accepted January 18, 2010

DOI: 10.3892/ijo_00000598

Abstract. The urokinase-type plasminogen activator receptor (uPAR) has diverse biological functions including roles in proteolysis, cell adhesion and cellular signaling. We identified a heat shock protein MRJ (DNAJB6) as a novel uPAR-interacting protein in a yeast two-hybrid screen and confirmed the interaction and co-localization by GST-pull down assays, and co-immunoprecipitation in cells transfected with MRJ. Endogenous interaction between uPAR and MRJ was also detected in breast cancer MDA-MB-231 cells. Deletion mapping demonstrated that the C-terminal region of MRJ is required to mediate its interaction with uPAR. To understand the biological function of the uPAR-MRJ complex, we determined whether MRJ regulated uPAR mediated adhesion to vitronectin in human embryonic kidney (HEK) 293 cells. After transfection with full length MRJ, there was a 50% increase in cell adhesion compared to the mock transfected control (p<0.01). This increase in adhesion is dependent on the uPAR/full length MRJ interaction as cells transfected with the mutant construct containing only N-terminal region or C-terminal region of MRJ had no increase in cell adhesion. The observed increase in adhesion to vitronectin by MRJ was also blocked by an anti-uPAR domain I antibody suggesting that the induced adhesion is at least in part contributed by uPAR on the cell surface. These data provide a novel mechanism by which uPAR plays a role in cell adhesion to vitronectin.

Introduction

Urokinase-type plasminogen activator (uPA) receptor (uPAR) has been implicated in multiple cellular pathways, including proteolysis, cell adhesion and signal transduction. The uPAR protein sequence has three repeats which form three homologous domains with ~90 amino acids each. These have been designated DI, DII and DIII from the N-terminal end (1). These domains are homologous to the CD59/Ly6 family (2) and have two short linker regions between DI and DII, as well as DII and DIII. Cleavage of uPAR by both chymotrypsin and uPA occurs in the linker region between DI and DII at residues 87 and 84, respectively, to result in a cleaved form of uPAR (3). There is also a soluble variant of uPAR that has been found in the media of cell lines and body fluids from cancer patients. This soluble form may be either the full-length receptor or a truncated form DIIDIII (4). Binding of uPA to its receptor can activate signal transduction pathways including the Ras/ERK pathway by a mechanism that requires FAK, Src, and Shc activation and induction of transient c-fos gene expression (5,6). In addition to the binding of uPA, several proteins have been found to be associated with uPAR functions or signalling pathways. These include integrins β1/2/3, vitronectin, cytokeratins 8/18, EGFR (epidermal growth factor receptor), PDGFR (platelet derived growth factor receptor), LDLR- (low density lipoprotein receptor-) related protein, FPR (FMLP-receptor), UPARAP and G-protein coupled receptors FPR1 (FMLP-receptor-like protein 1). These interactions with uPAR result in various functional consequences depending on the specific interacting protein (4,7-9). For example, integrin β1 interacts with uPAR and forms a uPA-uPAR-α5β1 complex initiating intracellular signalling (10). Vitronectin binds to uPAR, and once phosphorylated, regulates uPA-dependent cell adhesion. However,
the numerous and varied roles of uPAR in cell adhesion, migration, proliferation, angiogenesis and cancer metastasis are not completely explained by identified known protein interactions. Hence we hypothesized there are still additional and as yet unidentified proteins that interact with uPAR. These additional interacting proteins could bind to any of the multiple forms of uPAR as described, which can be located either as a GPI-anchored protein on the cell surface, as a cleaved soluble form, or within intracellular vesicles in the cytoplasm after internalization. In addition, recent crystalline structure modelling of uPAR has found the external surface of uPAR to be free to interact with other proteins even when bound to uPA (11). The yeast two-hybrid system has been used widely in studying intracellular protein-protein interactions. However, more recently, it has also been used successfully to investigate interactions between extracellular proteins such as perlecain (12), thrombospondin (13), EMILIN (14) and matrix metalloproteinase 2 (15). Furthermore, a member of the plasminogen activation system PAI-1 has been used directly as a bait on two occasions and found to interact with α1-acid glycoprotein (16) and α-actinin-4 (17). To identify novel uPAR partners and find functional significance of the interaction, we screened a breast cancer cDNA library with several bait constructs using a yeast two-hybrid approach. Here we show that the heat shock protein MRJ (mammalian relative DnaJ) interacts functionally with uPAR to increase uPAR mediated cell adhesion to vitronectin.

Materials and methods

Materials, vectors and yeast strains. The yeast vectors pGBD-B and pACT2-B and yeast strains PJ69-4A and PJ69-4α were kindly provided by Dr David Markie (Department of Pathology, Dunedin School of Medicine, New Zealand). The pRK5-myc-MRJ-F, pRK5-myc-MRJ-N1, pRK5-myc-MRJ-N2, pRK5-myc-MRJ-C, pACT2-MRJ-C and pACTα-MRJ-F were all kindly provided by Masaki Inagaki and Ichiro Izawa (Aichi Cancer Center Research Institute, Japan). The stable uPAR transfected human embryonic kidney (HEK) 293 cells were kindly provided by Dr Ying Wei (University of California, San Francisco). The anti-uPAR antibodies (nos. 3931, AF807, MAB807) were purchased from American Diagnostica Inc or R&D Systems, Inc. The mouse monoclonal anti-uPAR antibodies R2 and R3 were kindly provided by Dr Niels Behrendt (Copenhagen, Denmark). The mouse anti-human MRJ and anti-human DNAJB4 antibodies were purchased from Abnova Corp. (Taiwan). The anti-myc antibody and anti-β actin antibody were purchased from Sigma-Aldrich.

Expression cDNA library construction and cloning of open reading frames of uPAR baits. A human breast carcinoma cDNA library (18) was transformed on a large scale into PJ69-4α to construct a pre-transformed library of 4.7x10⁹ independent yeast colonies. Five uPAR baits were designed based on the uPAR full-length cDNA sequence and amplified by PCR using gene-specific primers that added short sequence tags (Fig. 1A) (19). The resulting DNA fragments were co-transformed into yeast host PJ69-4A with BamHI linearized pGBD-B vector DNA and plated with selection for the TRP1 gene. Individual colonies were tested by PCR for the presence of an insert with correct size.

Yeast two-hybrid screening and cloning of MRJ preys. A mating strategy described previously was used for the yeast two-hybrid screening (19). Briefly, library transformed PJ69-4α was grown in YPAD media. Bait plasmid transformed PJ69-4A yeast was grown overnight in a rich Trp-media (SD+C supplemented with 100 μg/ml leucine, 20 μg/ml histidine, 20 μg/ml uracil and 32 μg/ml adenine). A total of 5x10⁶ yeast cells of bait and library were used per screen. The resulting diploids were tested for HIS3, ADE2 and LacZ reporter gene activation. Secondary confirmation of interactions were done as described previously (19). Full-length pRK5-myc-MRJ-F, pRK5-myc-MRJ-N1, pRK5-myc-MRJ-N2, pRK5-myc-MRJ-C, pACT2-MRJ-C and pACTα-MRJ-F have been described previously (20).

Yeast two-hybrid cross mating. The pACT2-MRJ-C and pACTα-MRJ-F plasmids were transformed into PJ69-4α and then mated against the five uPAR bait constructs transformed in PJ69-4A yeast as described (21).

In vitro transcription and translation and GST-pull down assay. The TNT® T7 Quick coupled Rabbit Reticulocyte Transcription/Translation System (Promega, Madison, WI, USA) was used to label MRJ with [35S]-methionine. PCR reaction products for DI, DII, DIII, DIDIIDIII and DIDIIDDIII uPAR were used to clone into the N-terminal glutathione S-transferase (GST) containing pDEST™15 plasmid using the Gateway® System (Invitrogen, Carlsbad, CA, USA). GST-tagged protein was expressed and purified in BL21-AI™ E. coli using standard protocol and purified >50% glutathione-agarose bead slurry. Equivalent amount of GST-tagged uPAR protein was incubated with labelled MRJ protein and washed with pull down buffer [150 mM NaCl, 20 mM Tris-HCl (pH 7.5), 0.1% NP-40, 2.5 mg/ml BSA, 0.01% 2-ME, 1.2 mM PMSF]. Bound protein was eluted with 3X SDS loading buffer and separated by SDS-PAGE. The labelled bound protein was visualised by phosphor imager (Bio-Rad) and analyzed using the Quantity One Software (Bio-Rad).

Northern blotting. RNA was isolated from cells with TRIzol Reagent using standard protocols of Invitrogen. Northern blot analysis was carried out as described previously (22).

Cell culture, plasmid transfection and β-galactosidase assay. The human breast cancer MDA-MB-231 and HEK293 cell lines were maintained in DMEM medium supplemented with 10% fetal calf serum (FCS), and 1% antibiotics. The stable transfected HEK293/uPAR cell line was cultured in the presence of 0.9 mg/ml G418 (23) (Geneticin). Transfections were performed using Lipofectamine™ 2000 as per manufacturer's instructions (Invitrogen). Briefly, cells were transfected with recombinant or control vector and also pRSV-β-galactosidase plasmid to control for transfection efficiency. Whole cell lysates were prepared using reporter lysis buffer and β-galactosidase activity was measured using standard protocols (Promega).
any uncoated areas. Cells (1.5x10^5 cells/well) were seeded BSA (Sigma) overnight at 4˚C. Plates were rinsed with PBS, were pre-coated with 2 μg/ml vitronectin or heat-denatured previously with modifications (23). Briefly, 96-well dishes. The assay was performed as described Cell adhesion assay to samples to prevent co-migration of the heavy chain IgG isotype-matched IgG controls. The complex was collected anti-uPAR, anti-MRJ or anti-DNAJB4 antibodies and their isotype-matched IgG controls. MDA-MB-231 [rabbit anti-c-myc (C3956, Sigma), goat anti-uPAR (AF807), Rockford, IL, USA) before undergoing IP with antibodies Cell lysate was pre-cleared with protein G-agarose (Pierce, and the cells washed with PBS, and lysed with IP buffer. Following incubation for 48 h, the medium was removed, and the cells washed with PBS, and lysed with IP buffer. Cell lysate was pre-cleared with protein G-agarose (Pierce, Rockford, IL, USA) before undergoing IP with antibodies [rabbit anti-c-myc (C3956, Sigma), goat anti-uPAR (AF807), and their isotype-matched IgG controls]. MDA-MB-231 cells were lysed and treated as above but underwent IP with antibodies [anti-uPAR, anti-MRJ or anti-DNAJB4 antibodies and their isotype-matched IgG controls. The complex was collected and subjected to WB as described (22). No DTT was added to samples to prevent co-migration of the heavy chain IgG with the uPAR band (Fig. 5B).

Co-immunoprecipitation (coIP) and Western blotting (WB). HEK293/uPAR cells were transiently transfected with the pRK5-myc-MRJ-F plasmid with Lipofectamine 2000. Following incubation for 48 h, the medium was removed, and the cells washed with PBS, and lysed with IP buffer. Cell lysate was pre-cleared with protein G-agarose (Pierce, Rockford, IL, USA) before undergoing IP with antibodies [rabbit anti-c-myc (C3956, Sigma), goat anti-uPAR (AF807), and their isotype-matched IgG controls]. MDA-MB-231 cells were lysed and treated as above but underwent IP with antibodies [anti-uPAR, anti-MRJ or anti-DNAJB4 antibodies and their isotype-matched IgG controls. The complex was collected and subjected to WB as described (22). No DTT was added to samples to prevent co-migration of the heavy chain IgG with the uPAR band (Fig. 5B).

Cell adhesion assay. The assay was performed as described previously with modifications (23). Briefly, 96-well dishes were pre-coated with 2 μg/ml vitronectin or heat-denatured BSA (Sigma) overnight at 4˚C. Plates were rinsed with PBS, and all wells incubated with 2% heat-denatured BSA to block any uncoated areas. Cells (1.5x10^5 cells/well) were seeded in the coated wells and incubated for 2 h at 37˚C. After washing the attached cells were fixed with methanol/acetone and stained with 0.1% crystal violet. The stain was eluted using acetic acid/methanol/water and absorbance measured.

Statistical analysis. All values are expressed as the mean ± standard deviation and statistical significance calculated using Student’s t-tests where appropriate.

Results

Yeast two-hybrid screening and confirmation of cross-mating between uPAR and MRJ. As shown in Fig. 1A, five different uPAR baits, full-length uPAR (DIDIIDIII), domain II plus III (uPAR-DIDIIDIII), domain III (uPAR-DIII), domain II (uPAR-DII) and domain I (uPAR-DI) were constructed and used in subsequent yeast two-hybrid screen. A number of candidate proteins were identified by each bait (data not shown). Among the candidates, the C-terminal end of MRJ was identified by both the uPAR-DI (1/2 positive clones) and uPAR-DIDIIDIII (6/17 positive clones) baits (Fig. 1B). Following this initial identification of MRJ as a putative binding protein of uPAR, a number of deletion mutants based on the full length sequence of MRJ were used (Fig. 2A) to further assess the binding between uPAR and MRJ. To this end, a cross mating approach was undertaken between the yeast containing C-terminal fragment (MRJ-C) and the full-length MRJ (MRJ-F) prey and the five uPAR bait. Fig. 2B shows efficient mating between all five uPAR baits and MRJ-C prey containing strains (streaked in duplicate), as shown by growth on Leu-/Trp- drop out media. When uPAR-DIDIIDIII and MRJ-C were present in the same diploid colonies, there was strong activation of the HIS3, ADE2 and LacZ reporter genes. This activity was reduced for the uPAR-DI bait. There was only residual reporter gene activation in the uPAR-DIDIIDIII/MRJ-F and uPAR-DI/MRJ-F diploids, which may have been due to inefficient mating. There was no detectable reporter gene activation in diploids containing MRJ-F and uPAR-DII, uPAR-DIII or uPAR-DIDIIDIII. These results suggested that the uPAR/MRJ interaction occurred between the C-terminal domain of MRJ and DI or the full length DIDIIDIII uPAR.

uPAR interact with the C-terminal end of MRJ by GST-pull down assay. To confirm the interaction between uPAR and MRJ proteins, an in vitro GST-pull down assay was undertaken. To elucidate whether a particular domain of uPAR was involved in the interaction, different GST-tagged uPAR constructs were incubated with [35S]-methionine labelled MRJ-F. Fig. 3A suggested that MRJ-F may bind preferentially with GST-uPAR-DIDIIDIII and GST-uPAR-DI proteins, consistent with our yeast two-hybrid results. A second assay was employed to map the interaction domain in MRJ involved. Four alternate [35S]-methionine labelled MRJ constructs were incubated with the GST-uPAR-DIDIIDIII protein or GST alone (Fig. 3B). uPAR-DIDIIDIII bound strongly to MRJ-F and MRJ-C, but weakly to MRJ-N2 and not at all to MRJ-N1, indicating that the MRJ C-terminal domain is required for interactions with uPAR. This result implicates the C-terminal domain of MRJ as the predominant region for the interaction between uPAR and MRJ, with no apparent binding to the J-domain or the adjacent glycine/phenylalanine-rich (G/F) region.

uPAR and MRJ are co-expressed in cancer cell lines. To test whether uPAR and MRJ are co-expressed and to determine
a suitable cell line for further studies, we performed mRNA and protein analyses in human cancer cell lines (Fig. 4). High level expression of MRJ and uPAR mRNAs was notable in the MDA-MB-231 cell line compared to other cancer cell lines (Fig. 4A). There are two isoforms of human MRJ, isoform a (2.5 kb transcript variant I, NM_058246) and isoform b (1.6 kb transcript variant II, NM_005494). The variant II differs in the 3' coding region and has a distinct 3' UTR, compared to transcript variant I. The resulting isoform b is shorter and distinct, compared to isoform a. It is the shorter transcript variant II that encodes the MRJ isoform b that interacts with uPAR. To determine whether this mRNA expression was reflected at the protein level, Western blot analysis was carried out in HeLa, MDA-MB-231 and 143CTK cell lines. HEK293/uPAR cells transfected with myc-MRJ-F was used as a positive control. The major uPAR protein band occurred at ~55-60 kDa, with additional bands at 45 and 35 kDa corresponding to glycosylated, soluble and deglycosylated uPAR forms, respectively. Two endogenous MRJ protein bands were detected with apparent molecular weights of ~32 and ~45 kDa (Fig. 4B). uPAR and MRJ proteins are co-expressed in all four cell lines. The breast cancer cell line MDA-MB-231 showed the highest protein levels for both uPAR and MRJ proteins and was therefore selected for further studies.

Co-immunoprecipitation of uPAR and MRJ in HEK293/uPAR cells transfected with MRJ, and in the breast cancer cell line MDA-MB-231. To determine whether interactions between uPAR and MRJ also occur within a cellular context, coIP analyses were carried out using HEK293/uPAR cells that express high levels of uPAR. In this instance, the cells were transfected with myc-tagged MRJ-F for 48 h before the cells were lysed and subjected to IP with anti-uPAR or anti-myc antibody. As shown in Fig. 5A, three major bands were again evident after probing with anti-uPAR antibody as described above. These uPAR bands were detected in those samples immunoprecipitated with anti-uPAR or anti-myc antibodies, or whole cell lysate, but were either not or more weakly detected in the respective IgG isotype controls, indicating a specific interaction between uPAR and MRJ. After probing with anti-myc antibody (Fig. 5B), a myc-tagged MRJ-F protein band detected in the whole cell lysate and in samples immunoprecipitated with anti-uPAR but not with its isotype goat IgG antibody. As shown in Fig. 5A, three major bands were again evident after probing with anti-uPAR antibody as described above. These uPAR bands were detected in those samples immunoprecipitated with anti-uPAR or anti-myc antibodies, or whole cell lysate, but were either not or more weakly detected in the respective IgG isotype controls, indicating a specific interaction between uPAR and MRJ. After probing with anti-myc antibody (Fig. 5B), a myc-tagged MRJ-F protein band detected in the whole cell lysate and in samples immunoprecipitated with anti-uPAR but not with its isotype goat IgG antibody. The coIP of MRJ-F and uPAR in the HEK293/uPAR cell line provides evidence for an interaction between these two proteins in cultured cells.
As shown in Fig. 6, to detect the interaction between endogenously expressed uPAR and MRJ, coIP was performed using breast cancer MDA-MB-231 cells that express both uPAR and MRJ proteins. The uPAR protein was detected in lysate immunoprecipitated with anti-MRJ antibody, but not after coIP with the isotype mouse IgG control antibody (Fig. 6A). The MRJ protein was also detected after IP with anti-uPAR, but not after coIP with goat IgG control antibody (Fig. 6B). To determine whether uPAR specifically bound to MRJ (DNAJB6), MDA-MB-231 lysate was immunoprecipitated with DNAJB4, an antibody for another MRJ family member. After probing with anti-uPAR antibody (Fig. 6A), no uPAR proteins were detected. Similarly, MDA-MB-231 lysate was immunoprecipitated with anti-uPAR and probed with anti-DNAJB4 antibody (Fig. 6C), no DNAJB4 proteins were detected suggesting that the DNAJB4 protein may not bind to uPAR under these conditions. This experiment was an additional control to the standard IgG controls to determine specificity of the interaction between uPAR and MRJ. The coIP of uPAR and MRJ in MDA-MB-231 cells indicates that these proteins interact with each other when they express endogenously.

MRJ-F increases uPAR-dependent cellular adhesion to vitronectin. To test the biological significance of the uPAR-MRJ interaction, we next examined whether MRJ regulated uPAR-dependent adhesion to the ligand vitronectin in cell lines HEK293/uPAR/myc-MRJ-F cell lysate was used as a positive control to visualise both uPAR and MRJ protein bands. Western blotting for uPAR showed two predominant bands at ~55 and 35 kDa and a third minor band at ~45 kDa corresponding to glycosylated, deglycosylated and soluble uPAR respectively. The Western blotting for MRJ showed two predominant bands at ~32 and ~45 kDa which correspond to the two MRJ transcripts of 1.6 and 2.5 kb seen in the Northern blotting, respectively. ß-actin (42 kDa) was used as a loading control.
integrin receptor α5β1) and not to Vn. As shown in Fig. 7A, the adhesion potential to vitronectin of HEK293/uPAR cells transfected with MRJ-F was significantly increased compared with control vector PRK5 (p<0.01). However, no adhesion change was evident for the uPAR negative wild-type HEK293 cells transfected with MRJ-F. On the contrary, when tested on the fibronectin coated plates (Fig. 7B), the adhesion of HEK293/uPAR cells transfected with MRJ-F was less than the cells treated with PRK5 control vector (p<0.01), and there was no significant different in adhesion between the different treated wild-type HEK293 cells.

To determine whether the increase in adhesion to vitronectin was dependent on the C-terminal region critical of the interaction with uPAR, HEK293/uPAR cells transfected with MRJ-F was significantly increased compared with control vector PRK5 (p<0.01). However, no adhesion change was evident for the uPAR negative wild-type HEK293 cells transfected with MRJ-F. On the contrary, when tested on the fibronectin coated plates (Fig. 7B), the adhesion of HEK293/uPAR cells transfected with MRJ-F was less than the cells treated with PRK5 control vector (p<0.01), and there was no significant different in adhesion between the different treated wild-type HEK293 cells.

To determine whether the increase in adhesion to vitronectin was dependent on the C-terminal region critical of the interaction with uPAR, HEK293/uPAR cells transfected with full-length MRJ (MRJ-F), or its mutant containing only C-terminal domain (MRJ-C), or its mutant containing only N-terminal domain (MRJ-N1), or vector control (PRK5) (Fig. 7C). Moreover, to determine that the observed increase in adhesion to Vn is indeed due to uPAR, cells were also incubated with the specific blocking anti-domain I-uPAR antibody (R3). As shown in Fig. 7C, after transfection with MRJ-F, there was an ~50% increase in the number of adherent cells compared to the PRK5 transfected control (p<0.01). This increase in adhesion is predominantly due to uPAR as it can be reduced to basal levels by R3, an anti-domain I uPAR specific antibody. There were no significant changes in adhesion compared to the vector control when cells were transfected with either MRJ-C or MRJ-N1 construct suggesting that MRJ-C and MRJ-N1 proteins that contain C-terminal domain only or lack the C-terminal domain respectively, did not have the ability to increase adhesion to vitronectin.
of MRJ, with the shorter B-isoform (UniProtKB/Swiss-Prot subfamily B (DnaJB6) (NM_005494). There are two isoforms resulting in enhanced uPAR-dependent adhesion to vitronectin. MRJ interact with one another both of HSP70. Here, we report for the first time that uPAR and particular the heat shock protein (HSP) MRJ, a co-chaperon of potential candidate proteins that interacted with uPAR, in screening of a breast cancer cDNA library identified a number
designed and used in the yeast two-hybrid system. The

In this study, five truncated bait constructs of uPAR were designed and used in the yeast two-hybrid system. The screening of a breast cancer cDNA library identified a number of potential candidate proteins that interacted with uPAR, in particular the heat shock protein (HSP) MRJ, a co-chaperon of HSP70. Here, we report for the first time that uPAR and MRJ interact with one another both in vitro and in vivo, resulting in enhanced uPAR-dependent adhesion to vitronectin.

The MRJ protein is member 6 of the DnaJ/HSP40 homolog subfamily B (DnaJB6) (NM_005494). There are two isoforms of MRJ, with the shorter B-isoform (UniProtKB/Swiss-Prot entry O75190-2) homologous to the sequence identified in the yeast two-hybrid screen. The DnaJ family of proteins work together with the DnaK/HSP70 class of chaperones to assist in a wide array of protein folding processes in almost all cellular compartments (26). It has been found to be essential for embryonic development, as homozygous MRJ mutant mice die at mid-gestation due to the failure of chorioallantoic fusion (27). The specific nature of the MRJ mutant phenotype, despite several DnaJ-related genes being expressed in the placenta, suggested that these proteins do not have redundant functions (27). MRJ has also been found to be highly expressed in the brain and over-expression of MRJ in an in vitro Huntington disease model suppressed polyglutamine-dependent protein aggregation, caspase activity and cellular toxicity (28). More recently, the larger isoform of MRJ has been shown to negatively regulate tumour growth in breast cancer with the shorter version also speculated to modulate tumour growth (29).

In our yeast two-hybrid screening, MRJ was identified as a potential new interacting protein of uPAR for both the full-length uPAR-DIIDDIII and uPAR-DI baits. The interaction was confirmed using a cross-mating approach (Fig. 2). From the GST-pull down studies, the C-terminal end of MRJ was confirmed to bind specifically to uPAR, independent of either the N-terminal J-domain or the glycine/phenylalanine-rich domain. Further characterization found that MRJ bound with the greatest affinity to GST-tagged full-length uPAR-DIIDDIII followed by the GST-tagged uPAR-DI (Fig. 3). These data suggest that the interaction between the two proteins occurs mostly via uPAR domain I and the MRJ C-terminal domain. In the MDA-MB-231 and HEK293/uPAR cell lines either endogenous or transfected uPAR/MRJ proteins were able to co-IP (Figs. 5 and 6) confirming that the two proteins interacted in the cells.

HSPs protect cells from harmful conditions, including temperature elevation (heat shock), decrease in pH, oxidative stress and inflammation. Under non-stress conditions, they have multiple housekeeping functions including folding and translocating newly synthesized proteins, as well as activating signaling molecules. Recent findings indicate that cancer cells express high levels of HSPs which are closely correlated with poor prognosis (30). MRJ is an essential co-chaperone of HSP70, with the N-terminal J-domain necessary for its interaction with HSP70 and its chaperone activity (31,32). In breast cancer, similar to uPAR, HSP70 expression is correlated with metastasis and poor prognosis (33). We show here that the important uPAR/vitronectin interaction is also at least in part regulated by MRJ (Fig. 7). uPA- and its receptor-dependent cell adhesion to co-IP (Figs. 5 and 6) confirming that the two proteins interacted in the cells.
mechanism (35). Functionally the interaction between uPAR and vitronectin can promote both cellular adhesion and migration (24, 25, 36) and may direct uPAR to focal contacts (37, 38). The exact mechanism of how MRJ regulates uPAR to increase adhesion to vitronectin is currently being investigated. It has already been shown that the expression of uPAR in HEK293 cells leads to the formation of tight complexes with β1 integrins to promote the adhesion of these cells to vitronectin (39, 40). Human MRJ was also found to directly interact with the intermediate filament keratin 18 (K18), and regulated K8/18 filament organization (20). Indeed, both uPAR and PAI-1 have also been found to interact with keratin 18 (17, 41) and, MRJ has the ability to direct keratin 18 filaments to the proteasome (42). Furthermore, with the recent report highlighting the role of the longer MRJ isoform in breast cancer (29), these current studies offer a novel insight in offering a potential for the MRJ/uPAR interaction to modulate tumor growth by either altering keratin filament organization and/or promotion in vitronectin binding via β1 integrins. Further functional analyses of the novel interaction between uPAR and MRJ and its role in cell adhesion will provide more understanding of their respective roles in regulating cancer metastasis.

Acknowledgements

We thank Ai-Wei Quan for her technical assistance, Professor David Morris for his financial assistance and co-supervision to Z.L. and A.M. Professor Zichun Hua for providing helpful discussion. Professor G.A.C. Murrell for providing organization and/or promotion in vitronectin binding via β1 integrins. Further functional analyses of the novel interaction between uPAR and MRJ and its role in cell adhesion will provide more understanding of their respective roles in regulating cancer metastasis.

References


